Major tuberculosis vaccine trial completes enrollment faster than expected
A closely watched clinical trial testing what could be the world’s first new tuberculosis vaccine in a century has hit its enrollment target, ahead of expectations.
Related Articles
Pharma’s reputation with patient groups dips again, mostly due to pricing issues
For the second consecutive year, the pharma industry saw its reputation dip among patient advocacy groups, largely due to ongoing concerns over pricing issues.
U.S. government researchers present ‘phenomenal’ new data on HPV vaccines
A new study seems to confirm that a single dose of the vaccine used to prevent HPV infection is just as effective as two —…
Capricor Therapeutics forges ahead with FDA on Duchenne drug, despite political tumult
While there have been reports from drugmakers about possible interruptions with FDA matters due to staff layoffs, one company “hasn’t noticed any difference.”
Merck KGaA to purchase SpringWorks Therapeutics in deal worth more than $3 billion
After months of discussion, Germany’s Merck KGaA said it would buy SpringWorks Therapeutics.
U.S. government researchers present ‘phenomenal’ new data on HPV vaccines
A new study seems to confirm that a single dose of the vaccine used to prevent HPV infection is just as effective as two —…
HPV vaccine news ‘that will save millions of lives’ from cancer, and other AACR news
The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next generation of KRAS inhibitors.
Let’s talk tariffs, and no Amazon Prime subscription with your MA plan
This is the online version of STAT’s email newsletter Health Care Inc., delivered to your inbox every Monday.
U.S. government researchers present ‘phenomenal’ new data on HPV vaccines
A new study seems to confirm that a single dose of the vaccine used to prevent HPV infection is just as effective as two —…
AUA 2025: PIVOT-006: A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec Versus Surveillance for the Treatment of Intermediate-Risk NMIBC
AUA 2025, bladder cancer, non-muscle invasive bladder cancer (NMIBC), PIVOT-006 trial, Cretostimogene Grenadenorepvec Versus Surveillance for the Treatment of Intermediate-Risk non-muscle invasive bladder cancer, BCG-unresponsive…
U.S. government researchers present ‘phenomenal’ new data on HPV vaccines
A new study seems to confirm that a single dose of the vaccine used to prevent HPV infection is just as effective as two —…